AbbVie Elahere FDA Full Approval Analysis

Key Takeaways

• The FDA granted regular approval for Elahere on March 22, 2024 for FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer after one to three prior regimens.
• Confirmatory Phase 3 MIRASOL (NCT04209855) showed median OS 16.46 vs 12.75 months and median PFS 5.62 vs 3.98 months versus investigator-choice chemotherapy.
• AbbVie closed the ImmunoGen acquisition on February 12, 2024 at $31.26 per share, then inherited a fully approved ovarian ADC weeks later.
• For BD teams, the Elahere path shows how OS-positive confirmatory design can convert accelerated approvals inside roughly 16 months.

What did the FDA change on March 22, 2024?

On March 22, 2024, the FDA converted Elahere from accelerated to regular approval for adult patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who had received one to three prior systemic regimens, with patient selection by an FDA-approved test.

The agency’s public notice lists ImmunoGen, Inc. (now part of AbbVie) as the applicant and notes priority review. The same FRα-high platinum-resistant population that supported the November 2022 accelerated label remains the commercial beachhead for Elahere (mirvetuximab soravtansine-gynx).

What MIRASOL data unlocked full Elahere FDA approval?

MIRASOL randomized patients with high FRα-expressing platinum-resistant ovarian cancer to Elahere or investigator-choice single-agent chemotherapy (weekly paclitaxel, pegylated liposomal doxorubicin, or topotecan). Primary endpoint was investigator-assessed progression-free survival; key secondary endpoints included objective response rate and overall survival.

ImmunoGen’s May 3, 2023 SEC exhibit reported median OS of 16.46 months for Elahere versus 12.75 months for chemotherapy (HR 0.67; p=0.0046; 204 OS events as of March 6, 2023), a 33% reduction in risk of death. Median PFS was 5.62 versus 3.98 months. Those figures, not ORR alone, drove the sBLA conversion thesis.

Accelerated approval baseline from SORAYA

The FDA first granted accelerated approval in November 2022 on overall response rate and duration of response from the single-arm SORAYA study. That label created commercial access while requiring confirmatory evidence. MIRASOL was designed as that confirmatory trial under ClinicalTrials.gov identifier NCT04209855.

For regulatory strategists, the Elahere sequence is a clean accelerated-to-full conversion: biomarker-defined population, contemporaneous companion diagnostic path, and a randomized confirmatory study that prespecified clinically meaningful survival endpoints.

How AbbVie’s ImmunoGen deal priced the asset

AbbVie’s February 12, 2024 close of ImmunoGen at $31.26 per share brought Elahere into the solid-tumor ADC franchise before full U.S. approval landed. AbbVie’s SEC closing release called Elahere the first FDA-approved ADC in ovarian cancer and cited confirmatory evidence then under FDA review showing a survival benefit in platinum-resistant disease.

• Close date: February 12, 2024
• Cash consideration: $31.26 per ImmunoGen share
• FDA full approval: March 22, 2024 (about five weeks later)
• Trial ID anchoring confirmatory claims: NCT04209855

Investors reading the deal after March 22, 2024 no longer need to underwrite withdrawal risk if confirmatory OS had failed. That is the core change in the risk stack, not a new mechanism of action.

BD and competitive implications for FRα ADCs

Elahere’s full label raises the evidentiary bar for later FRα-targeting ADCs. Head-to-head or carefully designed non-inferiority work against an OS-positive standard becomes harder to avoid once payers and guidelines absorb survival data.

Differentiation will likely lean on ocular and other toxicity management, dosing convenience, combination regimens, or earlier-line expansion rather than another single-arm ORR package in the same platinum-resistant niche. Market-access teams should expect scrutiny of list price versus chemotherapy comparators that historically offered limited response rates and no OS advantage in this setting.

What remains unproven after full approval

Regular approval does not prove benefit in platinum-sensitive disease, front-line combinations, or non-ovarian FRα-positive tumors. Those label expansions remain clinical-development bets, not established facts on the March 22, 2024 FDA notice.

Independent long-term real-world OS, sequence after PARP inhibitors and bevacizumab, and cross-trial comparisons with newer ADCs are not settled by MIRASOL alone. Claims about “multi-billion-dollar” peak sales or Asia-Pacific launch timing are omitted here unless tied to a primary filing.

Related NovaPharma coverage

• Elahere (mirvetuximab soravtansine-gynx) drug profile
• AbbVie company profile
• Kelun-Biotech SKB118 approval analysis

Frequently Asked Questions

Primary Sources

1. FDA: Elahere regular approval (March 22, 2024)
2. SEC: ImmunoGen MIRASOL top-line results (May 3, 2023)
3. SEC: AbbVie completes ImmunoGen acquisition (Feb 12, 2024)
4. ClinicalTrials.gov: MIRASOL NCT04209855